TTD for patients with CLL and/or SLL treated with acalabrutinib or ibrutinib
| . | Number of patients∗ . | Total events, n (%) . | Events at 3 mo, n (%) . | Events at 6 mo, n (%) . | Events at 12 mo, n (%) . | Events at 18 mo, n (%) . | Median TTD, mo (95% CI) . | Mean TTD†, mo (95% CI) . | HR (95% CI) . |
|---|---|---|---|---|---|---|---|---|---|
| Unweighted‡ | |||||||||
| All patients receiving acalabrutinib | 353 | 82 (23.2) | 52 (14.7) | 69 (19.5) | 77 (21.8) | 80 (22.7) | NR (25.1-NR) | 23.6 (21.3-26.0) | 0.90 (0.72-1.14) |
| All patients receiving ibrutinib | 2244 | 878 (39.1) | 339 (15.1) | 492 (21.9) | 669 (29.8) | 757 (33.7) | 29.3 (27.7-33.2) | 23.6 (22.9-24.3) | ref. |
| ATT weighted§ | |||||||||
| All patients receiving acalabrutinib | 353 | 82 (23.2) | 52 (14.7) | 69 (19.5) | 77 (21.8) | 80 (22.7) | NR (25.1-NR) | 23.6 (21.3-26.0) | 0.70 (0.53-0.92) |
| All patients receiving ibrutinib | 364 | 119 (32.7) | 69 (19.0) | 92 (25.3) | 112 (30.8) | 115 (31.6) | 23.4 (18.1-28.7) | 21.4 (19.8-23.1) | ref. |
| ATT weighted with additional adjustment|| | |||||||||
| All patients receiving acalabrutinib | 353 | 82 (23.2) | 52 (14.7) | 69 (19.5) | 77 (21.8) | 80 (22.7) | NR (25.1-NR) | 23.6 (21.3-26.0) | 0.59 (0.43-0.81) |
| All patients receiving ibrutinib | 364 | 119 (32.7) | 69 (19.0) | 92 (25.3) | 112 (30.8) | 115 (31.6) | 23.4 (18.1-28.7) | 21.4 (19.8-23.1) | ref. |
| . | Number of patients∗ . | Total events, n (%) . | Events at 3 mo, n (%) . | Events at 6 mo, n (%) . | Events at 12 mo, n (%) . | Events at 18 mo, n (%) . | Median TTD, mo (95% CI) . | Mean TTD†, mo (95% CI) . | HR (95% CI) . |
|---|---|---|---|---|---|---|---|---|---|
| Unweighted‡ | |||||||||
| All patients receiving acalabrutinib | 353 | 82 (23.2) | 52 (14.7) | 69 (19.5) | 77 (21.8) | 80 (22.7) | NR (25.1-NR) | 23.6 (21.3-26.0) | 0.90 (0.72-1.14) |
| All patients receiving ibrutinib | 2244 | 878 (39.1) | 339 (15.1) | 492 (21.9) | 669 (29.8) | 757 (33.7) | 29.3 (27.7-33.2) | 23.6 (22.9-24.3) | ref. |
| ATT weighted§ | |||||||||
| All patients receiving acalabrutinib | 353 | 82 (23.2) | 52 (14.7) | 69 (19.5) | 77 (21.8) | 80 (22.7) | NR (25.1-NR) | 23.6 (21.3-26.0) | 0.70 (0.53-0.92) |
| All patients receiving ibrutinib | 364 | 119 (32.7) | 69 (19.0) | 92 (25.3) | 112 (30.8) | 115 (31.6) | 23.4 (18.1-28.7) | 21.4 (19.8-23.1) | ref. |
| ATT weighted with additional adjustment|| | |||||||||
| All patients receiving acalabrutinib | 353 | 82 (23.2) | 52 (14.7) | 69 (19.5) | 77 (21.8) | 80 (22.7) | NR (25.1-NR) | 23.6 (21.3-26.0) | 0.59 (0.43-0.81) |
| All patients receiving ibrutinib | 364 | 119 (32.7) | 69 (19.0) | 92 (25.3) | 112 (30.8) | 115 (31.6) | 23.4 (18.1-28.7) | 21.4 (19.8-23.1) | ref. |
ref., reference group.
Five patients in the ibrutinib cohort had a treatment discontinuation date that was the same as the index date (ie, initiation of ibrutinib) and were removed from the analysis.
Mean TTD was calculated as the area under the Kaplan-Meier curve until the end of follow-up.
Median follow-up time for the acalabrutinib and ibrutinib cohorts was 7.1 and 17.5 months, respectively, among the overall study population. Mean (min, max) follow-up time for the acalabrutinib and ibrutinib cohorts was 8.6 (0.1, 34.7) months and 17.8 (0.2, 37.9) months, respectively.
The following characteristics were adjusted for using ATT weights: age, sex, race, geographic region, year of ibrutinib or acalabrutinib initiation, year of CLL/SLL diagnosis, line of therapy, Rai stage, modified Quan-CCI score, atrial fibrillation, ECOG performance status, and use of anticoagulants. Median follow-up time for the ATT-weighted acalabrutinib and ibrutinib cohorts was 7.1 and 7.6 months, respectively, among the overall study population. Mean (min, max) follow-up time for the ATT-weighted acalabrutinib and ibrutinib cohorts was 8.6 (0.1, 34.7) months and 9.1 (0.02, 37.7) months, respectively.
Prior BTKi use was further controlled for in a doubly robust Cox PH model.